Copyright
©The Author(s) 1998.
World J Gastroenterol. Apr 15, 1998; 4(2): 147-149
Published online Apr 15, 1998. doi: 10.3748/wjg.v4.i2.147
Published online Apr 15, 1998. doi: 10.3748/wjg.v4.i2.147
Table 2 Results of single test of tumor markers
| Groups | Normal control | Pancreatic cancer | Non-pancreaticmali gnancy | Pancreatitis |
| POA (U/mL) | 84.80 ± 13.96 (1/40) | 252.5 ± 164.33 (19/28) | 136.37 ± 93.63 (9/62) | 101.98 ± 57.88 (1/15) |
| mPOA (mg/L) | 4.88 ± 1.96 (2/40) | 18.45 ± 10.57 (29/39) | 6.24 ± 3.82 (5/62) | 4.69 ± 1.52 (0/17) |
| PCAAc (mg/L) | 12.59 ± 6.34 (1/40) | 57.25 ± 82.93 (23/33) | 12.64 ± 5.14 (3/49) | 13.53 ± 9.91 (0/14) |
| PaA (μg/L) | 13.05 ± 3.84 (3/64) | 61.54 ± 45.59 (26/33) | 17.62 ± 10.31 (5/44) | 21.35 ± 11.83 (3/20) |
| HPE1 (μg/L) | 23.80 ± 3.40 (1/82) | 83.30 ± 73.40 (62/93) | 48.93 ± 54.63 (26/63) | 124.90 ± 168.30 (25/35) |
| E1 (ng/dL) | 276.60 ± 85.36 (0/10) | 1116.00 ± 1281.00 (10/16) | 1321.00 ± 2842.00 (9/13) | |
| CA19-9 (U/L) | 7.90 ± 9.74 (2/81) | 165.40 ± 128.03 (19/31) | 139.88 ± 121.72 (6/15) | |
| GPDA (U/L) | 54.84 ± 10.80 (0/60) | 101.02 ± 75.84 (14/33) | 64.89 ± 72.64 (27/69) | 50.94 ± 15.50 (2/25) |
| RNase (U/mL) | 58.19 ± 11.09 (1/30) | 92.22 ± 19.66 (16/20) | 65.88 ± 12.32 (5/20) | 67.95 ± 9.77 (2/15) |
| RNase I (U/mL) | 9.53 ± 13.43 (1/30) | 39.09 ± 39.31 (9/20) | 9.23 ± 8.98 (1/20) | 11.87 ± 11.30 (1/15) |
| RNase II (U/mL) | 50.75 ± 13.36 (0/30) | 52.78 ± 29.68 (5/20) | 56.89 ± 16.82 (0/20) | 60.17 ± 19.55 (1/15) |
| α1AT (mg/L) | 30.51 ± 6.35 (1/30) | 49.86 ± 18.47 (10/20) | 38.65 ± 16.30 (6/20) | 39.23 ± 10.02 (3/15) |
| CEA (mg/L) | 11.15 ± 2.95 (1/20) | 16.82 ± 10.26 (5/20) | 15.73 ± 11.98 (5/20) | 10.22 ± 3.42 (0/15) |
- Citation: Zhao XY, Yu SY, Da SP, Bai L, Guo XZ, Dai XJ, Wang YM. A clinical evaluation of serological diagnosis for pancreatic cancer. World J Gastroenterol 1998; 4(2): 147-149
- URL: https://www.wjgnet.com/1007-9327/full/v4/i2/147.htm
- DOI: https://dx.doi.org/10.3748/wjg.v4.i2.147